DUSA Files Form S-3 Shelf Registration Statement

Market Wire, May, 2008

DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® photodynamic therapy (PDT) and other products targeting patients with common skin conditions, today announced the filing of a shelf registration statement with the Securities and Exchange Commission. After the shelf registration statement has become effective, DUSA may, from time-to-time, offer its common stock, preferred stock, debt securities, depository shares and warrants up to an aggregate public offering price of up to $75 million. These securities may be offered, separately or together, in separate series, in amounts, at prices and on terms to be set forth in a filing with the Securities and Exchange Commission at the time of such offering.

The shelf registration statement is intended to provide DUSA with flexibility to raise funds from the offering of its securities in one or more offerings, subject to market conditions and DUSA's capital needs. There are no immediate plans to raise any funds.

Any offer to sell, or solicitation of an offer to buy securities, if and when such offer is made, will be pursuant to a prospectus supplement that will be issued in respect of any such offering. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan® PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp, and is being developed for the treatment of acne. DUSA's other dermatology products include ClindaReach(TM) and Nicomide®. DUSA is also supporting development of certain internal indications of Levulan® PDT. DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com .

Contacts: DUSA Pharmaceuticals, Inc. Robert F. Doman President & CEO (978) 909-2216 DUSA Pharmaceuticals, Inc. Richard Christopher VP Finance & CFO (978) 909-2211 DUSA Pharmaceuticals, Inc. Shari Lovell Director, Shareholder Services (978) 657-7500 ext. 1121 Website: www.dusapharma.com The Trout Group LLC Chad Rubin Investor Relations Contact (646) 378-2947